Serum Metrnl is associated with the presence and severity of coronary artery disease.
Serum Metrnl is associated with the presence and severity of coronary artery disease.
复制标题
血清 Metrnl 与冠状动脉疾病的存在和严重程度相关
DOI：
10.1111/jcmm.13915
复制
发表时间：
2019-01
影响因子：
5.3
通讯作者：
Lu X
中科院分区：
文献类型：
--
作者：
Liu ZX;Ji HH;Yao MP;Wang L;Wang Y;Zhou P;Liu Y;Zheng XF;He HW;Wang LS;Gao W;Lu X
镍纹蛋白样（Metrnl）是一种新型脂肪因子，在白色脂肪组织中高度表达。Metrnl刺激啮齿动物的能量消耗并改善葡萄糖耐量。然而，Metrnl是否在冠状动脉疾病（CAD）中起作用仍有待阐明。本研究旨在探讨中国患者血清Metrnl与CAD的相关性。共193例CAD患者和156例对照受试者入组本研究。通过酶联免疫吸附测定法测量血清Metrnl浓度。测量人体测量表型、空腹血糖、血脂和炎性细胞因子。冠心病组血清Metrnl水平明显低于对照组（132.41 vs 173.17 pg/mL，P < 0.001）。血清Metrnl与代谢参数呈负相关，包括体重指数、总胆固醇和低密度脂蛋白胆固醇以及炎症标志物，包括高敏C反应蛋白、IL-1β和IL-11，即使在调整潜在混杂变量后也是如此（P < 0.05）。在多变量逻辑回归分析中，与血清Metrnl水平最高三分位数的受试者相比，最低三分位数的受试者具有最高的CAD风险（校正OR = 2.63，95%CI = 1.46 - 4.27，P = 0.001）。校正潜在混杂变量后，血清Metrnl也随着狭窄血管数量的增加而降低（P < 0.001）。此外，Metrnl水平降低与通过Gensini评分量化的CAD严重程度呈负相关。该第一个病例对照研究显示血清Metrnl与CAD的存在和严重程度显著相关，表明Metrnl可能是CAD的新的有希望的治疗靶点。
Meteorin‐like (Metrnl) is a novel adipokine that is highly expressed in white adipose tissue. Metrnl stimulates energy expenditure and improves glucose tolerance in rodents. However, whether Metrnl plays a role in coronary artery disease (CAD) remains to be elucidated. The present study aimed to investigate the association of serum Metrnl with CAD in Chinese patients. A total of 193 patients with CAD and 156 control subjects were enrolled in this study. Serum Metrnl concentration was measured by enzyme‐linked immunosorbent assay. Anthropometric phenotypes, fasting glucose, serum lipids, and inflammatory cytokines were measured. Serum Metrnl was lower in CAD patients when compared to those controls (132.41 vs 173.17 pg/mL, P < 0.001). Serum Metrnl was negatively correlated with metabolic parameters, including body mass index, total cholesterol, and low‐density lipoprotein cholesterol as well as inflammatory markers including high‐sensitivity C‐reactive protein, IL‐1β, and IL‐11 even after adjustment for potential confounding variables (P < 0.05). In multivariable logistic regression analyses, compared to those in the highest tertile of serum Metrnl levels, subjects in the lowest tertile had the highest risks for CAD (adjusted OR = 2.63, 95% CI = 1.46‐4.27, P = 0.001). After adjustment for potential confounding variables, serum Metrnl was also decreased as the number of stenosed vessels increased (P < 0.001). Furthermore, decreased Metrnl level was negatively correlated with the severity of CAD quantified by the Gensini score. This first case‐control study shows significant associations of serum Metrnl with the presence and severity of CAD, suggesting Metrnl might be a new promising therapeutic target for CAD.
登录
查看更多内容
影响因子：
3.1
作者：
Wang, Hui;Luo, Wei;Eitzman, Daniel T.
通讯作者：
Eitzman, Daniel T.
影响因子：
5.1
作者：
Chung, Hye Soo;Hwang, Soon Young;Choi, Kyung Mook
通讯作者：
Choi, Kyung Mook
DOI：
10.1530/joe-16-0211
发表时间：
2016-12
期刊：
The Journal of endocrinology
影响因子：
--
作者：
Luo L;Liu M
通讯作者：
Liu M
Subfatin 是一种新型脂肪因子，与脂肪和大脑表达中的镍纹蛋白不同
影响因子：
5.5
作者：
Li, Zhi-Yong;Zheng, Si-Li;Miao, Chao-Yu
通讯作者：
Miao, Chao-Yu
影响因子：
5.1
作者：
Lee, Ju Hee;Kang, Yea Eun;Ku, Bon Jeong
通讯作者：
Ku, Bon Jeong